1
Nov
2022

ANFARM HELLAS S.A.

Exhibitor at CPHI Frankfurt 2022 stand 80B40, Integrated Pharma
About Us

Anfarm is a leading EU GMP Pharmaceuticals Manufacturer established in 1967, engaged in the development, production, licensing & sales of quality generic pharmaceuticals on a global scale. Our main activities include: 1. Licensing out & International Sales 2. Tech Transfer & Contract Manufacturing 3. Contract Development 4. New Product Development 5. Development / Optimization of Lyophilization Cycles 6. Regulatory Affairs Services

  • GR
  • 2015
    On CPHI since
Contact info
Event information
CPHI Frankfurt 2022
  • 1-3 November 2022
  • Messe Frankfurt, Germany
  • Visit us at stand 80B40, Integrated Pharma

Products Featured at CPHI Frankfurt 2022

  • Amikacin Inj.Sol 500mg/2ml (EU CTD Available) & 1g/4ml (EU CTD Available: Q3 2021)

    Product Amikacin Inj.Sol 500mg/2ml (EU CTD Available) & 1g/4ml (EU CTD Available: Q3 2021)

    Amikacin Solution for Injection 
    Reference Product: Briklin® / BRISTOL-MYERS SQUIBB
    Description: Amikacin sulfate is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species,&nb...
  • Apixaban F.C. Tabs 2.5mg/tab & 5mg/tab  (under development)

    Product Apixaban F.C. Tabs 2.5mg/tab & 5mg/tab (under development)

    Apixaban Film Coated Tablets 2.5mg & 5mg
    Reference Product: Eliquis® / Bristol-Myers Squibb/Pfizer
    Description: Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transie...
  • Azithromycin Pd.Sol.Inf 500mg/Vial (EU CTD Available)

    Product Azithromycin Pd.Sol.Inf 500mg/Vial (EU CTD Available)

    Azithromycin 500mg/Vial Powder for Solution for Infusion Reference Product: Zithromax® / PFIZER 
    Description: Azithromycin as powder for solution for infusion is indicated for the treatment of community-acquired pneumonia due to susceptible microorganisms in adult patients where initial intrav...
  • Brivaracetam Oral Solution 10mg/ml (EU CTD Available: Q4 2022)

    Product Brivaracetam Oral Solution 10mg/ml (EU CTD Available: Q4 2022)

    Brivaracetam 10mg/ml Oral Solution
    Reference Product: Briviact® / UCB
    Description: Brivaracetam is an antiepileptic agent which is indicated as adjunctive therapy in the treatment of partial onsetseizures with or without secondary generalization in adults, adolescents and children from 4 year...
  • Brivaracetam Sol. Inf 10mg/ml (5ml Vial) (EU CTD Available: Q3 2022)

    Product Brivaracetam Sol. Inf 10mg/ml (5ml Vial) (EU CTD Available: Q3 2022)

    Brivaracetam 10mg/ml (5ml Vial) Solution for Injection/Infusion
    Reference Product: Briviact® / UCB
    Description: Brivaracetam is an antiepileptic agent which is indicated as adjunctive therapy in the treatment of partial onsetseizures with or without secondary generalization in adults, adolescents and...